男性乳腺癌的研究进展
|
摘要
男性乳腺癌在临床上少见,发病率远低于女性乳腺癌,与乳腺癌家族史、BRCA2基因突变及体内雌激素水平升高等因素密切相关。以手术、内分泌治疗、放疗、化疗为主的多种治疗手段在治疗中综合应用,使该病疗效明显提高。现就男性乳腺癌的研究进展作一综述。
Male breast cancer is a rare clinical entity, its incidence is much lower than that in women, and is closely related to factors such as family history of breast cancer, BRCA2 gene mutation and increased circulating estrogen levels. The treatment effect of this condition has been significantly improved by the integrated application of multiple treatment modalities that mainly include surgical management, endocrine therapy, chemotherapy and radiotherapy. Here, the authors address the research progress of male breast cancer.
Male breast cancer is a rare clinical entity, its incidence is much lower than that in women, and is closely related to factors such as family history of breast cancer, BRCA2 gene mutation and increased circulating estrogen levels. The treatment effect of this condition has been significantly improved by the integrated application of multiple treatment modalities that mainly include surgical management, endocrine therapy, chemotherapy and radiotherapy. Here, the authors address the research progress of male breast cancer.
引文
[1]Siegel RL,Miller KD,Jemal A.Cancer statistics,2019[J].CACancer J Clin,2019,69(1):7-34.doi:10.3322/caac.21551.
[2]Liu N,Johnson KJ,Ma CX.Male Breast Cancer:An Updated Surveillance,Epidemiology,and End Results Data Analysis[J].Clin Breast Cancer,2018,18(5):e997-e1002.doi:10.1016/j.clbc.2018.06.013.
[3]Sánchez-Mu?oz A,Vicioso L,Santonja A,et al.Male breast cancer:correlation between immunohistochemical subtyping and PAM50intrinsic subtypes,and the subsequent clinical outcomes[J].Mod Pathol,2018,31(2):299-306.doi:10.1038/modpathol.2017.129.
[4]Pritzlaff M,Summerour P,McFarland R,et al.Male breast cancer in a multi-gene panel testing cohort:insights and unexpected results[J].Breast Cancer Res Treat,2017,161(3):575-586.doi:10.1007/s10549-016-4085-4.
[5]Gargiulo P,Pensabene M,Milano M,et al.Long-term survival and BRCA status in male breast cancer:a retrospective single-center analysis[J].BMC Cancer,2016,16:375.doi:10.1186/s12885-016-2414-y.
[6]Silvestri V,Barrowdale D,Mulligan AM,et al.Male breast cancer in BRCA1 and BRCA2 mutation carriers:pathology data from the Consortium of Investigators of Modifiers of BRCA1/2[J].Breast Cancer Res,2016,18(1):15.doi:10.1186/s13058-016-0671-y.
[7]Ottini L,Silvestri V,Rizzolo P,et al.Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients:results from a collaborative multicenter study in Italy[J].Breast Cancer Res Treat,2012,134(1):411-418.doi:10.1007/s10549-012-2062-0.
[8]de Juan I,Palanca S,Domenech A,et al.BRCA1 and BRCA2mutations in males with familial breast and ovarian cancer syndrome.Results of a Spanish multicenter study[J].Fam Cancer,2015,14(4):505-513.doi:10.1007/s10689-015-9814-z.
[9]Momozawa Y,Iwasaki Y,Parsons MT,et al.Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and11,241 controls[J].Nat Commun,2018,9(1):4083.doi:10.1038/s41467-018-06581-8.
[10]Daly MB,Pilarski R,Berry M,et al.NCCN Guidelines Insights:Genetic/Familial High-Risk Assessment:Breast and Ovarian,Version 2.2017[J].J Natl Compr Canc Netw,2017,15(1):9-20.
[11]Liang M,Zhang Y,Sun C,et al.Association Between CHEK2*1100delC and Breast Cancer:A Systematic Review and Meta-Analysis[J].Mol Diagn Ther,2018,22(4):397-407.doi:10.1007/s40291-018-0344-x.
[12]Hultborn R,Hanson C,K?pf I,et al.Prevalence of Klinefelter's syndrome in male breast cancer patients[J].Anticancer Res,1997,17(6D):4293-4297.
[13]Keinan-Boker L,Levine H,Leiba A,et al.Adolescent obesity and adult male breast cancer in a cohort of 1,382,093 men[J].Int JCancer,2018,142(5):910-918.doi:10.1002/ijc.31121.
[14]Brinton LA,Carreon JD,Gierach GL,et al.Etiologic factors for male breast cancer in the U.S.Veterans Affairs medical care system database[J].Breast Cancer Res Treat,2010,119(1):185-192.doi:10.1007/s10549-009-0379-0.
[15]Little MP,McElvenny DM.Male Breast Cancer Incidence and Mortality Risk in the Japanese Atomic Bomb SurvivorsDifferences in Excess Relative and Absolute Risk from Female Breast Cancer[J].Environ Health Perspect,2017,125(2):223-229.doi:10.1289/EHP151.
[16]Grundy A,Harris SA,Demers PA,et al.Occupational exposure to magnetic fields and breast cancer among Canadian men[J].Cancer Med,2016,5(3):586-596.doi:10.1002/cam4.581.
[17]Laouali N,Pilorget C,Cyr D,et al.Occupational exposure to organic solvents and risk of male breast cancer:a European multicenter case-control study[J].Scand J Work Environ Health,2018,44(3):310-322.doi:10.5271/sjweh.3717.
[18]Vermeulen MA,Slaets L,Cardoso F,et al.Pathological characterisation of male breast cancer:Results of the EORTC10085/TBCRC/BIG/NABCG International Male Breast Cancer Program[J].Eur J Cancer,2017,82:219-227.doi:10.1016/j.ejca.2017.01.034.
[19]Wenhui Z,Shuo L,Dabei T,et al.Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment[J].Eur J Endocrinol,2014,171(4):527-533.doi:10.1530/EJE-14-0278.
[20]Yu XF,Feng WL,Miao LL,et al.The prognostic significance of molecular subtype for male breast cancer:a 10-year retrospective study[J].Breast,2013,22(5):824-827.doi:10.1016/j.breast.2013.02.005.
[21]Sun B,Zhang LN,Zhang J,et al.The prognostic value of clinical and pathologic features in nonmetastatic operable male breast cancer[J].Asian J Androl,2016,18(1):90-95.doi:10.4103/1008-682X.154992.
[22]Wang W,Xu X,Tian B,et al.Clinical features of patients with male breast cancer in Shanxi province of China from 2007 to 2016[J].JInvestig Med,2019,67(3):699-705.doi:10.1136/jim-2018-000823.
[23]Leone J,Zwenger AO,Leone BA,et al.Overall Survival of Men and Women With Breast Cancer According to Tumor Subtype:APopulation-based Study[J].Am J Clin Oncol,2019,42(2):215-220.doi:10.1097/COC.0000000000000497.
[24]Kornegoor R,Verschuur-Maes AH,Buerger H,et al.Molecular subtyping of male breast cancer by immunohistochemistry[J].Mod Pathol,2012,25(3):398-404.doi:10.1038/modpathol.2011.174.
[25]Nilsson C,Johansson I,Ahlin C,et al.Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact[J].Acta Oncol,2013,52(1):102-109.doi:10.3109/0284186X.2012.711952.
[26]Piscuoglio S,Ng CK,Murray MP,et al.The Genomic Landscape of Male Breast Cancers[J].Clin Cancer Res,2016,22(16):4045-4056.doi:10.1158/1078-0432.CCR-15-2840.
[27]Zhu X,Ying J,Wang F,et al.Estrogen receptor,progesterone receptor,and human epidermal growth factor receptor 2 status in invasive breast cancer:a 3,198 cases study at National Cancer Center,China[J].Breast Cancer Res Treat,2014,147(3):551-555.doi:10.1007/s10549-014-3136-y.
[28]Masci G,Caruso M,Caruso F,et al.Clinicopathological and Immunohistochemical Characteristics in Male Breast Cancer:ARetrospective Case Series[J].Oncologist,2015,20(6):586-592.doi:10.1634/theoncologist.2014-0243.
[29]Abreu MH,Afonso N,Abreu PH,et al.Male breast cancer:Looking for better prognostic subgroups[J].Breast,2016,26:18-24.doi:10.1016/j.breast.2015.12.001.
[30]Humphries MP,Sundara Rajan S,Honarpisheh H,et al.Characterisation of male breast cancer:a descriptive biomarker study from a large patient series[J].Sci Rep,2017,7:45293.doi:10.1038/srep45293.
[31]Cardoso F,Bartlett JMS,Slaets L,et al.Characterization of male breast cancer:results of the EORTC 10085/TBCRC/BIG/NABCGInternational Male Breast Cancer Program[J].Ann Oncol,2018,29(2):405-417.doi:10.1093/annonc/mdx651.
[32]Leone JP,Leone J,Zwenger AO,et al.Locoregional treatment and overall survival of men with T1a,b,cN0M0 breast cancer:A population-based study[J].Eur J Cancer,2017,71:7-14.doi:10.1016/j.ejca.2016.10.038.
[33]Bateni SB,Davidson AJ,Arora M,et al.Is Breast-Conserving Therapy Appropriate for Male Breast Cancer Patients?A National Cancer Database Analysis[J].Ann Surg Oncol,2019.doi:10.1245/s10434-019-07159-4.[Epub ahead of print]
[34]Zaenger D,Rabatic BM,Dasher B,et al.Is Breast Conserving Therapy a Safe Modality for Early-Stage Male Breast Cancer?[J].Clin Breast Cancer,2016,16(2):101-104.doi:10.1016/j.clbc.2015.11.005.
[35]Fogh S,Kachnic LA,Goldberg SI,et al.Localized therapy for male breast cancer:functional advantages with comparable outcomes using breast conservation[J].Clin Breast Cancer,2013,13(5):344-349.doi:10.1016/j.clbc.2013.05.004.
[36]Martin-Marcuartu JJ,Alvarez-Perez RM,Sousa Vaquero JM,et al.Selective sentinel lymph node biopsy in male breast cancer[J].Rev Esp Med Nucl Imagen Mol,2018,37(3):146-150.doi:10.1016/j.remn.2017.09.004.
[37]Maráz R,Boross G,Pap-Szekeres J,et al.The role of sentinel node biopsy in male breast cancer[J].Breast Cancer,2016,23(1):85-91.doi:10.1007/s12282-014-0535-1.
[38]Saha D,Tannenbaum S,Zhu Q.Treatment of Male Breast Cancer by Dual Human Epidermal Growth Factor Receptor 2(HER2)Blockade and Response Prediction Using Novel Optical Tomography Imaging:A Case Report[J].Cureus,2017,9(7):e1481.doi:10.7759/cureus.1481.
[39]Bender PFM,de Oliveira LL,Costa CR,et al.Men and women show similar survival rates after breast cancer[J].J Cancer Res Clin Oncol,2017,143(4):563-571.doi:10.1007/s00432-016-2311-4.
[40]Leon-Ferre RA,Giridhar KV,Hieken TJ,et al.A contemporary review of male breast cancer:current evidence and unanswered questions[J].Cancer Metastasis Rev,2018,37(4):599-614.doi:10.1007/s10555-018-9761-x.
[41]Abrams MJ,Koffer PP,Wazer DE,et al.Postmastectomy Radiation Therapy Is Associated With Improved Survival in Node-Positive Male Breast Cancer:A Population Analysis[J].Int J Radiat Oncol Biol Phys,2017,98(2):384-391.doi:10.1016/j.ijrobp.2017.02.007.
[42]Di Lauro L,Pizzuti L,Barba M,et al.Efficacy of chemotherapy in metastatic male breast cancer patients:a retrospective study[J].JExp Clin Cancer Res,2015,34:26.doi:10.1186/s13046-015-0143-8.
[43]Yu X F,Wang C,Chen B,et al.The effect of adjuvant chemotherapy in male breast cancer:134 cases from a retrospective study[J].ESMO Open,2017,2(2):e000134.doi:10.1136/esmoopen-2016-000134.
[44]Patten DK,Sharifi LK,Fazel M.New approaches in the management of male breast cancer[J].Clin Breast Cancer,2013,13(5):309-314.doi:10.1016/j.clbc.2013.04.003.
[45]Hong JH,Ha KS,Jung YH,et al.Clinical Features of Male Breast Cancer:Experiences from Seven Institutions Over 20Years[J].Cancer Res Treat,2016,48(4):1389-1398.doi:10.4143/crt.2015.410.
[46]Venigalla S,Carmona R,Guttmann DM,et al.Use and Effectiveness of Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer in Men[J].JAMA Oncol,2018,4(10):e181114.doi:10.1001/jamaoncol.2018.1114.
[47]Eggemann H,Ignatov A,Smith BJ,et al.Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients[J].Breast Cancer Res Treat,2013,137(2):465-470.doi:10.1007/s10549-012-2355-3.
[48]Eggemann H,Altmann U,Costa SD,et al.Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer[J].J Cancer Res Clin Oncol,2018,144(2):337-341.doi:10.1007/s00432-017-2539-7.
[49]Doyen J,Italiano A,Largillier R,et al.Aromatase inhibition in male breast cancer patients:biological and clinical implications[J].Ann Oncol,2010,21(6):1243-1245.doi:10.1093/annonc/mdp450.
[50]Hayashi H,Kimura M,Yoshimoto N,et al.A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment[J].Breast Cancer,2009,16(2):136-140.doi:10.1007/s12282-008-0060-1.
[51]Severson TM,Zwart W.A review of estrogen receptor/androgen receptor genomics in male breast cancer[J].Endocr Relat Cancer,2017,24(3):R27-34.doi:10.1530/ERC-16-0225.
[52]Christenson JL,Trepel JB,Ali HY,et al.Harnessing a Different Dependency:How to Identify and Target Androgen ReceptorPositive Versus Quadruple-Negative Breast Cancer[J].Horm Cancer,2018,9(2):82-94.doi:10.1007/s12672-017-0314-5.
[2]Liu N,Johnson KJ,Ma CX.Male Breast Cancer:An Updated Surveillance,Epidemiology,and End Results Data Analysis[J].Clin Breast Cancer,2018,18(5):e997-e1002.doi:10.1016/j.clbc.2018.06.013.
[3]Sánchez-Mu?oz A,Vicioso L,Santonja A,et al.Male breast cancer:correlation between immunohistochemical subtyping and PAM50intrinsic subtypes,and the subsequent clinical outcomes[J].Mod Pathol,2018,31(2):299-306.doi:10.1038/modpathol.2017.129.
[4]Pritzlaff M,Summerour P,McFarland R,et al.Male breast cancer in a multi-gene panel testing cohort:insights and unexpected results[J].Breast Cancer Res Treat,2017,161(3):575-586.doi:10.1007/s10549-016-4085-4.
[5]Gargiulo P,Pensabene M,Milano M,et al.Long-term survival and BRCA status in male breast cancer:a retrospective single-center analysis[J].BMC Cancer,2016,16:375.doi:10.1186/s12885-016-2414-y.
[6]Silvestri V,Barrowdale D,Mulligan AM,et al.Male breast cancer in BRCA1 and BRCA2 mutation carriers:pathology data from the Consortium of Investigators of Modifiers of BRCA1/2[J].Breast Cancer Res,2016,18(1):15.doi:10.1186/s13058-016-0671-y.
[7]Ottini L,Silvestri V,Rizzolo P,et al.Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients:results from a collaborative multicenter study in Italy[J].Breast Cancer Res Treat,2012,134(1):411-418.doi:10.1007/s10549-012-2062-0.
[8]de Juan I,Palanca S,Domenech A,et al.BRCA1 and BRCA2mutations in males with familial breast and ovarian cancer syndrome.Results of a Spanish multicenter study[J].Fam Cancer,2015,14(4):505-513.doi:10.1007/s10689-015-9814-z.
[9]Momozawa Y,Iwasaki Y,Parsons MT,et al.Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and11,241 controls[J].Nat Commun,2018,9(1):4083.doi:10.1038/s41467-018-06581-8.
[10]Daly MB,Pilarski R,Berry M,et al.NCCN Guidelines Insights:Genetic/Familial High-Risk Assessment:Breast and Ovarian,Version 2.2017[J].J Natl Compr Canc Netw,2017,15(1):9-20.
[11]Liang M,Zhang Y,Sun C,et al.Association Between CHEK2*1100delC and Breast Cancer:A Systematic Review and Meta-Analysis[J].Mol Diagn Ther,2018,22(4):397-407.doi:10.1007/s40291-018-0344-x.
[12]Hultborn R,Hanson C,K?pf I,et al.Prevalence of Klinefelter's syndrome in male breast cancer patients[J].Anticancer Res,1997,17(6D):4293-4297.
[13]Keinan-Boker L,Levine H,Leiba A,et al.Adolescent obesity and adult male breast cancer in a cohort of 1,382,093 men[J].Int JCancer,2018,142(5):910-918.doi:10.1002/ijc.31121.
[14]Brinton LA,Carreon JD,Gierach GL,et al.Etiologic factors for male breast cancer in the U.S.Veterans Affairs medical care system database[J].Breast Cancer Res Treat,2010,119(1):185-192.doi:10.1007/s10549-009-0379-0.
[15]Little MP,McElvenny DM.Male Breast Cancer Incidence and Mortality Risk in the Japanese Atomic Bomb SurvivorsDifferences in Excess Relative and Absolute Risk from Female Breast Cancer[J].Environ Health Perspect,2017,125(2):223-229.doi:10.1289/EHP151.
[16]Grundy A,Harris SA,Demers PA,et al.Occupational exposure to magnetic fields and breast cancer among Canadian men[J].Cancer Med,2016,5(3):586-596.doi:10.1002/cam4.581.
[17]Laouali N,Pilorget C,Cyr D,et al.Occupational exposure to organic solvents and risk of male breast cancer:a European multicenter case-control study[J].Scand J Work Environ Health,2018,44(3):310-322.doi:10.5271/sjweh.3717.
[18]Vermeulen MA,Slaets L,Cardoso F,et al.Pathological characterisation of male breast cancer:Results of the EORTC10085/TBCRC/BIG/NABCG International Male Breast Cancer Program[J].Eur J Cancer,2017,82:219-227.doi:10.1016/j.ejca.2017.01.034.
[19]Wenhui Z,Shuo L,Dabei T,et al.Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment[J].Eur J Endocrinol,2014,171(4):527-533.doi:10.1530/EJE-14-0278.
[20]Yu XF,Feng WL,Miao LL,et al.The prognostic significance of molecular subtype for male breast cancer:a 10-year retrospective study[J].Breast,2013,22(5):824-827.doi:10.1016/j.breast.2013.02.005.
[21]Sun B,Zhang LN,Zhang J,et al.The prognostic value of clinical and pathologic features in nonmetastatic operable male breast cancer[J].Asian J Androl,2016,18(1):90-95.doi:10.4103/1008-682X.154992.
[22]Wang W,Xu X,Tian B,et al.Clinical features of patients with male breast cancer in Shanxi province of China from 2007 to 2016[J].JInvestig Med,2019,67(3):699-705.doi:10.1136/jim-2018-000823.
[23]Leone J,Zwenger AO,Leone BA,et al.Overall Survival of Men and Women With Breast Cancer According to Tumor Subtype:APopulation-based Study[J].Am J Clin Oncol,2019,42(2):215-220.doi:10.1097/COC.0000000000000497.
[24]Kornegoor R,Verschuur-Maes AH,Buerger H,et al.Molecular subtyping of male breast cancer by immunohistochemistry[J].Mod Pathol,2012,25(3):398-404.doi:10.1038/modpathol.2011.174.
[25]Nilsson C,Johansson I,Ahlin C,et al.Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact[J].Acta Oncol,2013,52(1):102-109.doi:10.3109/0284186X.2012.711952.
[26]Piscuoglio S,Ng CK,Murray MP,et al.The Genomic Landscape of Male Breast Cancers[J].Clin Cancer Res,2016,22(16):4045-4056.doi:10.1158/1078-0432.CCR-15-2840.
[27]Zhu X,Ying J,Wang F,et al.Estrogen receptor,progesterone receptor,and human epidermal growth factor receptor 2 status in invasive breast cancer:a 3,198 cases study at National Cancer Center,China[J].Breast Cancer Res Treat,2014,147(3):551-555.doi:10.1007/s10549-014-3136-y.
[28]Masci G,Caruso M,Caruso F,et al.Clinicopathological and Immunohistochemical Characteristics in Male Breast Cancer:ARetrospective Case Series[J].Oncologist,2015,20(6):586-592.doi:10.1634/theoncologist.2014-0243.
[29]Abreu MH,Afonso N,Abreu PH,et al.Male breast cancer:Looking for better prognostic subgroups[J].Breast,2016,26:18-24.doi:10.1016/j.breast.2015.12.001.
[30]Humphries MP,Sundara Rajan S,Honarpisheh H,et al.Characterisation of male breast cancer:a descriptive biomarker study from a large patient series[J].Sci Rep,2017,7:45293.doi:10.1038/srep45293.
[31]Cardoso F,Bartlett JMS,Slaets L,et al.Characterization of male breast cancer:results of the EORTC 10085/TBCRC/BIG/NABCGInternational Male Breast Cancer Program[J].Ann Oncol,2018,29(2):405-417.doi:10.1093/annonc/mdx651.
[32]Leone JP,Leone J,Zwenger AO,et al.Locoregional treatment and overall survival of men with T1a,b,cN0M0 breast cancer:A population-based study[J].Eur J Cancer,2017,71:7-14.doi:10.1016/j.ejca.2016.10.038.
[33]Bateni SB,Davidson AJ,Arora M,et al.Is Breast-Conserving Therapy Appropriate for Male Breast Cancer Patients?A National Cancer Database Analysis[J].Ann Surg Oncol,2019.doi:10.1245/s10434-019-07159-4.[Epub ahead of print]
[34]Zaenger D,Rabatic BM,Dasher B,et al.Is Breast Conserving Therapy a Safe Modality for Early-Stage Male Breast Cancer?[J].Clin Breast Cancer,2016,16(2):101-104.doi:10.1016/j.clbc.2015.11.005.
[35]Fogh S,Kachnic LA,Goldberg SI,et al.Localized therapy for male breast cancer:functional advantages with comparable outcomes using breast conservation[J].Clin Breast Cancer,2013,13(5):344-349.doi:10.1016/j.clbc.2013.05.004.
[36]Martin-Marcuartu JJ,Alvarez-Perez RM,Sousa Vaquero JM,et al.Selective sentinel lymph node biopsy in male breast cancer[J].Rev Esp Med Nucl Imagen Mol,2018,37(3):146-150.doi:10.1016/j.remn.2017.09.004.
[37]Maráz R,Boross G,Pap-Szekeres J,et al.The role of sentinel node biopsy in male breast cancer[J].Breast Cancer,2016,23(1):85-91.doi:10.1007/s12282-014-0535-1.
[38]Saha D,Tannenbaum S,Zhu Q.Treatment of Male Breast Cancer by Dual Human Epidermal Growth Factor Receptor 2(HER2)Blockade and Response Prediction Using Novel Optical Tomography Imaging:A Case Report[J].Cureus,2017,9(7):e1481.doi:10.7759/cureus.1481.
[39]Bender PFM,de Oliveira LL,Costa CR,et al.Men and women show similar survival rates after breast cancer[J].J Cancer Res Clin Oncol,2017,143(4):563-571.doi:10.1007/s00432-016-2311-4.
[40]Leon-Ferre RA,Giridhar KV,Hieken TJ,et al.A contemporary review of male breast cancer:current evidence and unanswered questions[J].Cancer Metastasis Rev,2018,37(4):599-614.doi:10.1007/s10555-018-9761-x.
[41]Abrams MJ,Koffer PP,Wazer DE,et al.Postmastectomy Radiation Therapy Is Associated With Improved Survival in Node-Positive Male Breast Cancer:A Population Analysis[J].Int J Radiat Oncol Biol Phys,2017,98(2):384-391.doi:10.1016/j.ijrobp.2017.02.007.
[42]Di Lauro L,Pizzuti L,Barba M,et al.Efficacy of chemotherapy in metastatic male breast cancer patients:a retrospective study[J].JExp Clin Cancer Res,2015,34:26.doi:10.1186/s13046-015-0143-8.
[43]Yu X F,Wang C,Chen B,et al.The effect of adjuvant chemotherapy in male breast cancer:134 cases from a retrospective study[J].ESMO Open,2017,2(2):e000134.doi:10.1136/esmoopen-2016-000134.
[44]Patten DK,Sharifi LK,Fazel M.New approaches in the management of male breast cancer[J].Clin Breast Cancer,2013,13(5):309-314.doi:10.1016/j.clbc.2013.04.003.
[45]Hong JH,Ha KS,Jung YH,et al.Clinical Features of Male Breast Cancer:Experiences from Seven Institutions Over 20Years[J].Cancer Res Treat,2016,48(4):1389-1398.doi:10.4143/crt.2015.410.
[46]Venigalla S,Carmona R,Guttmann DM,et al.Use and Effectiveness of Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer in Men[J].JAMA Oncol,2018,4(10):e181114.doi:10.1001/jamaoncol.2018.1114.
[47]Eggemann H,Ignatov A,Smith BJ,et al.Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients[J].Breast Cancer Res Treat,2013,137(2):465-470.doi:10.1007/s10549-012-2355-3.
[48]Eggemann H,Altmann U,Costa SD,et al.Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer[J].J Cancer Res Clin Oncol,2018,144(2):337-341.doi:10.1007/s00432-017-2539-7.
[49]Doyen J,Italiano A,Largillier R,et al.Aromatase inhibition in male breast cancer patients:biological and clinical implications[J].Ann Oncol,2010,21(6):1243-1245.doi:10.1093/annonc/mdp450.
[50]Hayashi H,Kimura M,Yoshimoto N,et al.A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment[J].Breast Cancer,2009,16(2):136-140.doi:10.1007/s12282-008-0060-1.
[51]Severson TM,Zwart W.A review of estrogen receptor/androgen receptor genomics in male breast cancer[J].Endocr Relat Cancer,2017,24(3):R27-34.doi:10.1530/ERC-16-0225.
[52]Christenson JL,Trepel JB,Ali HY,et al.Harnessing a Different Dependency:How to Identify and Target Androgen ReceptorPositive Versus Quadruple-Negative Breast Cancer[J].Horm Cancer,2018,9(2):82-94.doi:10.1007/s12672-017-0314-5.